Cargando…
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Autores principales: | Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, d’Onofrio, Florindo, Albanese, Maria, Cetta, Ilaria, Di Fiore, Paola, Zucco, Maurizio, Filippi, Massimo, Bono, Francesco, Altamura, Claudia, Proietti, Stefania, Bonassi, Stefano, Vernieri, Fabrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172000/ https://www.ncbi.nlm.nih.gov/pubmed/35672670 http://dx.doi.org/10.1186/s10194-022-01434-8 |
Ejemplares similares
-
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022) -
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022) -
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
por: Barbanti, Piero, et al.
Publicado: (2023) -
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022) -
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021)